![Foto de Antonio](/img/nophoto.png)
Antonio
González Martín
Consultor Médico
Publicaciones (232) Publicaciones de Antonio González Martín
2024
-
A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial
Future oncology (London, England), Vol. 20, Núm. 13, pp. 799-809
-
An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial)
International Journal of Gynecological Cancer, Vol. 34, Núm. 6, pp. 942-945
-
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/ MINOVA Study)
Clinical Cancer Research, Vol. 30, Núm. 1, pp. 176-186
-
Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer
European Journal of Cancer, Vol. 202
-
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266
-
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
Journal of Clinical Oncology, Vol. 42, Núm. 1, pp. 47-58
-
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Gynecologic Oncology, Vol. 187, pp. 128-138
-
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
Gynecologic Oncology, Vol. 184, pp. 168-177
-
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study
Gynecologic Oncology, Vol. 186, pp. 182-190
-
Prognostic value of systemic inflammation response indexes obtained from the complete blood count in patients treated for advanced ovarian carcinoma in front line
Clinical and Translational Oncology
-
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
Bulletin du Cancer, Vol. 111, Núm. 3, pp. 277-284
2023
-
Association of Multiple High-Risk Factors on Observed Outcomes in Real-World Patients With Advanced Ovarian Cancer Treated With First-Line Therapy
JCO clinical cancer informatics, Vol. 7, pp. e2200189
-
Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: A stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601
International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 929-936
-
Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus
Journal of gynecologic oncology, Vol. 34, Núm. 5, pp. e57
-
Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation
Cancers, Vol. 15, Núm. 13
-
GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles
Cell Reports Medicine, Vol. 4, Núm. 12
-
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
Gynecologic Oncology, Vol. 178, pp. 119-129
-
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
Annals of Oncology, Vol. 34, Núm. 10, pp. 833-848
-
Novel therapies leading to a new landscape in gynecologic tumors
International Journal of Gynecological Cancer
-
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
Annals of Oncology, Vol. 34, Núm. 8, pp. 681-692